LONDON, June 07, 2018 (GLOBE NEWSWIRE) -- InMed is a Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Through its biosynthesis platform, the company believes it has distinct advantages over both naturally sourced and chemically synthesized cannabinoids, which could give it access to both the medical and retail markets, although the process is still in development. The company is also developing a proprietary pipeline, including INM-750 for epidermolysis bullosa (EB), a serious orphan indication, and expects to file an IND for INM-750 in H219.
We arrive at our valuation of C$221m or C$1.45 per basic share (C$1.20 per diluted share) based on a risk-adjusted NPV analysis. Because of the early stage of InMed’s proprietary pipeline, we only attribute a value of C$11m to it, although that will change as it progresses into the clinic. The company ended its fiscal Q318 (31 March) with C$13.9m in cash and we estimate this provides a runway into FY20.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Maxim Jacobs, +1 646 653 7027
Dr Nathaniel Wilkinson, +1 646 653 7036
healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube